Close menu




biotech

Photo credits: pixabay.com

Commented by Matthias Schomber on November 18th, 2026 | 05:36 CET

A three-way look: What Allianz shareholders, BioNTech investors and HPQ Silicon speculators should know now!

  • biotech
  • cancer drugs
  • cancer pipeline
  • coronavirus
  • vaccination
  • mrna
  • battery
  • rechargeable battery
  • rechargeable battery technology
  • battery cells
  • rechargeable battery cell
  • nanotechnology
  • drones
  • drone technology
  • insurance
  • insurance business

Created and published on behalf of HPQ Silicon
Allianz is delivering impressive record results. Vaccine specialist BioNTech continues to advance its oncology pipeline. Canadian small-cap HPQ Silicon may once again be on the verge of a promising technical breakout, as it was several years ago. Whether it is fundamental strength in the insurance sector, billion-dollar research bets in biotech and cancer drugs or speculative technology potential in batteries and energy storage, the following sections examine the opportunities, risks and financial data of these three very different stocks, providing investors with valuable guidance for their next strategic portfolio decisions.

Read

Commented by Matthias Schomber on November 9th, 2026 | 05:43 CET

Palantir Shares in Turmoil! Evotec Gains Momentum! Buying Opportunity in Lahontan Gold After the Consolidation!

  • biotech
  • evotec
  • palantir
  • intelligence service
  • ai
  • authorities
  • states
  • gold
  • lahontan
  • lahontan gold
  • gold mine
  • pea
  • gold production

Chip stocks are posting double-digit percentage declines. Investors fear the AI bubble could burst or that growth may no longer continue at the same pace. Corporate spending could be scaled back. Dutch bank ING is offering a portfolio of around USD 500 million in data centre loans for sale. This could indicate an attempt to pass on the risk. Investors are now desperately searching for the real winners of today and tomorrow beyond the broader market crowd. While AI software giant Palantir is also struggling with share price declines, biotech pioneer Evotec is seeking to embark on the painful road to recovery. The commodities sector also offers exciting opportunities, such as Lahontan Gold. Find out in the following article which fundamental data and technical levels really matter now for Palantir, Evotec and Lahontan Gold and where the opportunities for your portfolio may lie!

Read

Commented by Matthias Schomber on October 30th, 2026 | 05:27 CET

BioNTech seeks a breakthrough with its cancer pipeline, DroneShield battles short sellers and Cardiol Therapeutics targets a rebound!

  • biotech
  • rebound
  • technical analysis
  • droneshield
  • biontech
  • cardiol
  • therapeutics
  • moderna
  • cancer
  • pipeline

Created and published on behalf of Cardiol Therapeutics

Biotech heavyweights such as BioNTech and defence and drone stocks such as DroneShield are currently looking for unambiguous and clear trend signals. While BioNTech is grappling with clinical setbacks and internal discussions despite strategic collaborations, defence specialist DroneShield is weighed down by persistent short-selling pressure and rather subdued growth expectations. At the same time, Cardiol Therapeutics is coming into focus as a technically promising candidate that, following a correction lasting several months, could now find the long-awaited bottom at a prominent technical support zone. This equity analysis of the 3 stocks examines the financial data, operational milestones and strategic opportunities as well as the risks of the three companies to provide guidance that is as well-founded as possible. Read on to find out where attractive opportunities are now emerging.

Read

Commented by Matthias Schomber on October 23rd, 2026 | 05:42 CEST

Puma Boardroom Shake-Up, Margin Pressure at BYD and Clinical Milestones at BioNxt Solutions

  • electric cars
  • puma
  • sporting goods
  • adidas
  • nike
  • bionext
  • biotech

Sportswear manufacturer Puma is pressing ahead with its strategic realignment following a change of ownership and the arrival of Anta Sports as a shareholder. Chinese electric vehicle group BYD is grappling with regulatory hurdles and declining export margins. In the advanced drug delivery segment, BioNxt Solutions is attracting investors' attention with clinical progress and an interesting chart pattern. This article analyses the opportunities and risks of these three stocks. A close look at their fundamentals and technicals shows where key entry and turning points could lie for investors in the coming days and weeks.

Read

Commented by Fabian Lorenz on October 23rd, 2026 | 05:38 CEST

Strong News and Buy Recommendations: Vonovia, Evotec and Lahontan Gold

  • precious metals
  • gold
  • silver
  • biotechnology
  • real estate

Strong news from Lahontan Gold. The explorer has published a positive preliminary economic assessment (PEA) for its Santa Fe gold-silver project in Nevada. The after-tax net present value stands at approximately USD 820 million, significantly exceeding the company's current market capitalisation. The company is also working to expand the resource base. While Lahontan Gold shareholders can look forward to the approaching start of gold production, Vonovia shareholders face an uncertain future. The expropriation scenario is weighing on sentiment. Even JPMorgan's assessment that these concerns are exaggerated does little to change the picture. In a worst-case scenario, the German government would intervene. And what about Evotec? The shares have gained more than 10% in recent trading days. The appointment of a new executive at Novo Nordisk could inject fresh momentum into the company.

Read